Supporting the GLP-1 Journey with SEBiotic® & SlimSEB™
GLP-1 drugs like Ozempic and Wegovy are reshaping weight management. The results are undeniable—but the side effects are too. That’s why companion solutions aren’t optional anymore. They’re essential.
Why Gut Health Matters with GLP-1s
GLP-1 agonists slow digestion, which helps with weight loss but can also lead to issues. Up to 70% of GLP-1 users deal with nausea, bloating, constipation and diarrhea.
These side effects don’t just create discomfort; they can lead to dropout, derail outcomes and erode consumer trust.
For brands, the opportunity is clear: provide support that keeps consumers on track, and you gain loyalty that lasts.
A Market on Fire
Right now, 6% of adults in the U.S. take a GLP-1 drug. Millions more are considering them. By 2035, the market is projected to triple—jumping from $4.1 billion to $13 billion.
This growth creates massive demand for companion products that help consumers stay comfortable, nourished and committed to their weight management journey.
Science-Backed Gut Support
 |
SEBiotic® (Bacillus coagulans) is a shelf-stable, spore-forming probiotic backed by 14 clinical and in vitro studies. Unlike more fragile probiotics, SEBiotic® is shelf and heat-stable, and survives the journey through the GI tract in greater numbers to confer health benefits in your final formulation. |
Key Benefits
- Supports overall gut health
- Promotes a balanced gut microbiome
- Survives heat, processing & storage
- Withstands stomach acid in greater numbers
- Non-GMO Project verified
- Kosher & Halal certified
Clinical Results That Matter
SEBiotic® doesn’t just look good on paper—it delivers.
Clinical studies demonstrate
- Abdominal Relief: 63% of participants in the test group reported complete resolution of discomfort in 5 days vs 13% in the placebo group
- Constipation Resolution: improvement for 98.6% of study participants
- IBS Symptom Reduction: Significant improvements in bloating/cramping (78%), diarrhea/constipation (64%) & abdominal pain (80%)
Regulatory Confidence
After a rigorous scientific review of its safety and efficacy, SEBiotic® was granted a GRAS (Generally Recognized as Safe) No Objections Letter from the FDA.
Following an evaluation of extensive scientific evidence, Health Canada approved the following NPN (Natural Product Number) claims for SEBiotic®:
- Helps to relieve symptoms of irritable bowel syndrome (IBS), such as abdominal pain, bloating, cramping and nausea
- Helps support a healthy gut flora
- Source of probiotics
- Supports the maintenance of digestive health
This combination of clinical evidence and regulatory trust makes SEBiotic® a standout for brands aiming to support GLP-1 users.
Weight Management, During & Beyond GLP-1 Use
|
While SEBiotic® focuses primarily on gut support and comfort, SlimSEB™ is the ideal companion for weight management—whether consumers are on GLP-1s, transitioning off or seeking a natural, clean-label alternative. SlimSEB™ is a revolutionary blend of enzymes, probiotics and herbal extracts clinically shown to support metabolic health and weight management. |
 |
Ingredients in SlimSEB™
- Support weight management with or without GLP-1 use
- Promote metabolic health
- Convert sugar into fiber, supporting satiety & gut health
- Modulate hunger hormones
- Support lipid metabolism
- Support digestion & nutrient absorption
Clinical Highlights
In just 84 days, SlimSEB™ demonstrated measurable results
That’s meaningful progress on weight, metabolic and cardiovascular markers—all in under three months.
A Smarter Path Forward
The GLP-1 wave isn’t slowing down. Millions will enter the journey; millions will transition off, and millions more will search for alternatives. Brands that meet their needs will lead the next decade in the GLP-1 adjacent wellness space.
SEBiotic® offers demonstrated gut support to help keep consumers consistent. SlimSEB™ provides a novel, clinically supported approach to weight management—with or without GLP-1 drugs.
Together, they offer a powerful toolkit for any formulator to design products that support comfort, results and confidence.
Ready to build your next winning product? Let’s talk about bringing SEBiotic® and SlimSEB™ into your formulations today.
- GLP-1 side effects only one factor driving patient discontinuation rates. BioSpace. (2025, March 10). Enhancing GLP-1 benefits with protein intake. PURIS. (2025, February 11).
- Future Market Insights. (2025, July 16). GLP-1 nutritional support market size & share 2025-2035. Future Market Insights.
- Maity, C., Gupta, A.K. A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. Eur J Clin Pharmacol 75, 21–31 (2019).
- Gupta, A. K., & Maity, C. (2021). Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine, 3, 100.
- Rathi A, Pagare R. Efficacy and Safety of Bacillus coagulans LBSC in Drug Induced Constipation Associated With Functional Gastrointestinal Disorder: A Double-Blind, Randomized, Interventional, Parallel, Controlled Trial a Clinical Study on Bacillus coagulans LBSC for Drug Induced Constipation Associated With FGIDs. Glob Adv Integr Med Health. 2024 Sep 17;13:27536130241286511. doi: 10.1177/27536130241286511. PMID: 39295947; PMCID: PMC11409293.
- Chiranjit Maity, Anil Kumar Gupta, PhD, Dina B. Saroj, Atul Biyani, Pratik Bagkar, Jayshree Kulkarni & Yogini Dixit (2021) Impact of a Gastrointestinal Stable Probiotic Supplement Bacillus coagulans LBSC on Human Gut Microbiome Modulation, Journal of Dietary Supplements, 18:6, 577-596, DOI: 10.1080/19390211.2020.1814931
- Dina B. Saroj, Anil K. Gupta, Genome based safety assessment for Bacillus coagulans strain LBSC (DSM 17654) for probiotic application. International Journal of Food Microbiology, Volume 318, 2020, 108523, ISSN 0168-1605.
- Maity, C., Bagkar, P., Dixit, Y., Tiwari, A., & Gupta, A. K. (2020). Process and Storage Stability of Bacillus coagulans LBSC in Food Matrices and Appraisal of Calorific Restriction: B. coagulans LBSC stability and calorie restriction. Applied Food Biotechnology, 8(1), 57–69.
- Rathi A., Safety and Efficacy of SlimSEB in Overweight and Obese Subjects with the Risks of Type 2 Diabetes Mellitus. Advanced Enzymes Proprietary study, 2025.
